Sino Biological has now launched recombinant HA, NA, and NP proteins for 2022-2023 influenza vaccine strains, adding to its comprehensive collection of influenza antigens from all WHO-recommended vaccine strains in recent years. These antigens can be used to analyze vaccine-induced antibody response.